We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

Key points New evidence has led to a change in the way that some patients with amyotrophic lateral sclerosis (ALS) are classified and treated. Based on the findings of a landmark trial,[1][1] the drug ...

Key points The health implications of exposures to the Alberta oil sands are underresearched, despite more than a decade of calls from Indigenous communities and researchers for further investigation.

Background: Consent forms have become too long and often do little to help people understand the risk elements of their participation in research, instead focusing on risk reduction for research ...

A 24-year-old man was brought by ambulance to a rural hospital after a motor vehicle collision. On physical examination, he was hemodynamically unstable with a blood pressure of 60/40 mm Hg and a ...

Semaglutide, liraglutide, lixisenatide, dulaglutide, and tirzepatide are the current GLP1RAs available in Canada. These are approved for the treatment of type 2 diabetes and obesity and have been used ...

Diagnosis of loperamide abuse requires a high index of suspicion Loperamide is not detected by routine drug screens. Typically, a patient with loperamide abuse will have a history of opioid misuse or ...

Key points Dried plasma is dehydrated, powdered human plasma. Once mixed with sterile water, the reconstituted plasma delivers essential coagulation factors necessary for hemostasis and supports ...

Key points More than a decade after the launch of Canada’s Strategy for Patient-Oriented Research (SPOR), patient engagement is increasingly expected across the health research ecosystem.

Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in ...

Association between frailty and 30-day outcomes after discharge from hospital ...